Clinical Trial Results - Iopofosine I 131 demonstrated an overall response rate (ORR) of 83.6% and a major response rate (MRR) of 58.2% in the CLOVER-WaM study, exceeding the primary endpoint of a 20% MRR [1] - The results were presented at the 66th Annual American Society of Hematology Conference in December 2024 [1] Product Pipeline - The company's lead asset is iopofosine I 131, a Phospholipid Drug Conjugate (PDC) designed for targeted delivery of iodine-131 [7] - Other pipeline assets include CLR 121225 (actinium-225 based program) and CLR 121125 (iodine-125 Auger-emitting program) targeting solid tumors [7] - The company is advancing radioconjugate PDC programs, including alpha- and Auger-emitting radioconjugates, into Phase 1/2a solid tumor studies [8] Regulatory and Market Strategy - Iopofosine I 131 has received six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations from the FDA [4] - The company is pursuing conditional U.S. market approval through the FDA's accelerated approval process and aligning with the European Medicines Agency for global approval [5] - A confirmatory study with 40-60 patients per arm is expected to be completed within 18 months of the first patient enrollment [5] Strategic Initiatives - The company plans to advance iopofosine I 131 through internal development, strategic partnerships, and other approaches [8] - CLR 121225, an alpha-emitting actinium-225 radioconjugate, has shown activity in pancreatic, colorectal, and breast cancer animal models, with an IND application planned for Q1 2025 [9] - The company is evaluating the timing of study initiation for both CLR 121225 and CLR 121125 [6] Corporate Updates - The company will present its 2025 strategic initiatives at the Biotech Showcase during the 43rd Annual JP Morgan Healthcare Conference in January 2025 [8] - A live webcast and replay of the presentation will be available on the company's investor relations website [10]

On Tuesday, Cellectar Biosciences, Inc. CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer.Due to recent communications with the FDA regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the company has decided to pursue strategic options for the further development and commercialization of this product candidate.Also Read: Cancer-Focused Cellec ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Conference Call November 18, 2024 8:30 AM ET Company Participants Anne Marie Fields - Managing Director, Precision AQ Jim Caruso - President & CEO Chad Kolean - CFO Andrei Shustov - SVP, Medical Shane Lea - Chief Commercial Officer Jarrod Longcor - COO Conference Call Participants Jeff Jones - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. And welcome at this time, all participants are in listen only mode. Following the presen ...

Exhibit 99.1 Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66 Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise up to an additional $73.3 million Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., November 18, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a latestage ...

Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise up to an additional $73.3 million Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs ...

Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [mark one] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 1-36598 CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ...

NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs FLORHAM PARK, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the signing of a strategic supply agreement with NorthStar Medical Radioisotopes, LLC, for the procurement of NorthStar’s non-carrier added (n.c ...

INDIANAPOLIS and FLORHAM PARK, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, and Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, have signed a commercial supply agreement for the manufacture of Cellectar’s first-in-class cancer therapy, iopofosine I 131. "We continue strengthening our supply netw ...

FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Monday, November 18, 2024Time:8:30 am E ...

FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31, 2024, from Nasdaq, Inc. informing the Company that it had regained compliance with Nasdaq Listing Rule 5250(c)(1). The Company filed the following on October 29, 2024, with the Securities and Exchange Commission: (i) restated audited consolidated financial statements for the fiscal years ended December 31, 20 ...